APOTEX CORP. for APOTEX CORP.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 18, 2010 | $150,000 | Replaced |
| 2nd Quarter - Report | Jul 19, 2010 | $150,000 | Replaced |
| 2nd Quarter - Amendment | Jul 19, 2010 | $150,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
S. 1315/HR 3777 the Drug Price Competition Act of 2009 S. 369, the Preserve Access to Affordable Generics Act HR 4899 EAH, Supplemental Disaster Relief and Summer Jobs Act of 2010, Chapter 2, Section 4201, Preserve Access to Affordable Generics Act SA 4361 to HR 4213 concerning market blockages caused by pharmaceutical patent settlements HR 759, Food and Drug Administration Globalization Act of 2009 Pharmaceutical waste disposal
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.